Pacira BioSciences will see its common stock suspended from the marketplace on November 18, 2026, with the final trading date confirmed for November 16, 2026, at a fixed cash payout of $36.50 per share.
Pacira BioSciences (PCRX) will be delisted after its merger: the last trading day is set for November 16, 2026, with suspension effective November 18, 2026, at $36.50 per share in cash. Any remaining discount of the share price below $36.50 should narrow toward the fixed merger consideration before the last trading date. The alert itself contains no new valuation information beyond confirming the timetable and payout.
Pacira BioSciences, Inc. (PCRX) is set to conclude its public trading tenure as part of a finalized merger agreement. Shareholders are slated to receive a fixed cash consideration of $36.50 per share upon the completion of the transaction.
Each share will be converted into $36.50 in cash. The last day to trade the stock is November 16, 2026, and it is suspended from the marketplace on November 18, 2026.
If the stock trades below $36.50 before the final trading date of November 16, 2026, the gap should close as holders receive the fixed cash consideration, but any remaining spread carries the risk that the merger process is not completed as scheduled.